Bausch Health (English Wikipedia)

"bausch-health". Violation Tracker. goodjobsfirst.org. Retrieved 2 May 2025. Good Jobs First is a national advocacy organization that tracks corporate accountability legislation, including job quality standards.

healio.com (Global: low place; English: low place)

Robert Stott (May 23, 2023). "Court upholds Bausch Health victory in Xifaxan fight; Norwich generic blocked until 2029". Healio Gastroenterology.

huffingtonpost.ca (Global: 2,253^rd place; English: 1,475^th place)

"Valeant Pharmaceuticals Subpeonaed In U.S. After Price-Gouging Allegations". New York: The Huffington Post via The Canadian Press and the Associated Press. October 15, 2015. Retrieved October 15, 2015.

institutionalinvestor.com (Global: 6,763^rd place; English: 3,694^th place)

Hacked Printers. Fake Emails. Questionable Friends. Fahmi Quadir Was Up 24% Last Year, But It Came at a Price. Institutional Investor, 9 January 2019

labusinessjournal.com (Global: low place; English: 6,428^th place)

"Panic Gone, New ICN Team Finds Finances in Disarray". Los Angeles Business Journal. 29 July 2002. Archived from the original on 11 January 2018. Retrieved 10 January 2018.

nytimes.com (Global: 7^th place; English: 7^th place)

"Shareholders Approve ICN Pharmaceuticals Merger". The New York Times. November 3, 1994.
Pollack, Andrew; Tavernise, Sabrina (October 4, 2015). "Valeant's Drug Price Strategy Enriches It, but Infuriates Patients and Lawmakers". The New York Times. ISSN 0362-4331. Retrieved October 4, 2015.
Pollack, Andrew (September 20, 2015). "Drug Goes From $13.50 a Tablet to $750, Overnight". The New York Times. Retrieved October 15, 2015.
Morgenson, Gretchen (October 2, 2015). "Valeant's High-Price Drug Strategy". The New York Times. Retrieved October 2, 2015.
Alexandra Stevenson; Matthew Goldstein (April 27, 2016), "As Valeant Tumbles, So Does Bill Ackman's Hedge Fund Herd", The New York Times, retrieved April 28, 2016
"Bausch Health Plans $1.21 B Settlement Over Stock Plunge". The New York Times. Associated Press. 2019-12-16. ISSN 0362-4331. Retrieved 2019-12-16.

ocregister.com (Global: 1,086^th place; English: 618^th place)

"Allergan Fight Conjures Ghost of O.C.'s Past". The Orange County Register. 19 May 2014.

pressreader.com (Global: 953^rd place; English: 647^th place)

van der Linde, Damon (October 22, 2015). "Valeant stocks plunge, trading halted". Calgary Herald. Retrieved October 22, 2015.
Van der Linde, Damon (16 October 2015). "Valeant Pharmaceuticals pricing controversy attracts scrutiny". Calgary Herald. Retrieved 16 October 2015.

prnewswire.com (Global: 406^th place; English: 258^th place)

"ICN Pharmaceuticals, Inc. Changes Its Name To Valeant Pharmaceuticals International" (Press release). PRNewswire. November 12, 2003. Archived from the original on April 9, 2016. Retrieved March 28, 2016.
"Valeant to Acquire Tecnofarma, A Mexican Generic Company" (Press release). PRNewswire. July 29, 2009. Archived from the original on April 5, 2016. Retrieved March 23, 2016.
"Valeant to Acquire Laboratoire Dr. Renaud in Canada" (Press release). PRNewswire. December 7, 2009. Archived from the original on April 5, 2016. Retrieved March 23, 2016.
"Valeant to Acquire Branded Generics/OTC Company in Brazil" (Press release). PRNewswire. March 19, 2010.
"Valeant to Acquire Vital Science Corp. in Canada" (Press release). April 28, 2010.
"Valeant Pharmaceuticals Completes Acquisition of Aton Pharma, Inc" (Press release). PRNewswire. May 27, 2010.
"Valeant and Biovail Complete Merger" (Press release). PRNewswire. September 28, 2010.
"Valeant Pharmaceuticals to Acquire PharmaSwiss S.A." (Press release). PR Newswire. February 1, 2011.
"Valeant Pharmaceuticals Agrees to Acquire Certain Assets from Atlantis Pharma in Mexico" (Press release). PR Newswire. April 18, 2012.
"Valeant Pharmaceuticals Agrees to Acquire Sanitas Group for Approximately EUR314 Million in Cash" (Press release). PR Newswire. May 24, 2011. Retrieved October 7, 2014.
"Valeant Pharmaceuticals Agrees to Acquire iNova" (Press release). PR Newswire. November 20, 2011. Retrieved October 7, 2014.
"Valeant Pharmaceuticals Completes Acquisition of Dermik" (Press release). PR Newswire. December 19, 2011. Retrieved October 7, 2014.
"Valeant Pharmaceuticals Acquires Probiotica in Brazil" (Press release). PR Newswire. February 1, 2012. Retrieved October 7, 2014.
"Valeant Pharmaceuticals to Acquire Eyetech" (Press release). PR Newswire. February 13, 2012. Retrieved October 7, 2014.
"Valeant Pharmaceuticals to Acquire Pedinol" (Press release). PR Newswire. April 12, 2012. Retrieved October 7, 2014.
"Valeant Pharmaceuticals Agrees to Acquire Certain Assets from Atlantis Pharma in Mexico" (Press release). PR Newswire. April 18, 2012.
"Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical" (Press release). PR Newswire. May 3, 2012.
"Valeant Pharmaceuticals Agrees To Acquire OraPharma" (Press release). PR Newswire. June 15, 2012. Retrieved October 7, 2014.
"Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash" (Press release). PR Newswire. September 3, 2012.
"Valeant Completes Acquisition Of Natur Produkt In Russia" (Press release). PR Newswire. February 1, 2013. Retrieved October 7, 2014.
"Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash" (Press release). PR Newswire. March 20, 2013. Retrieved October 7, 2014.
"Valeant Pharmaceuticals International, Inc. To Acquire Bausch + Lomb For $8.7 Billion" (Press release). PR Newswire. May 27, 2013.
"Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Solta Medical, Inc" (Press release). PRNewswire. January 23, 2014.
"Valeant Pharmaceuticals Completes Acquisition Of PreCision Dermatology" (Press release). PRNewswire. July 8, 2014.
"Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd" (Press release). PRNewswire. April 1, 2015.
"Valeant Pharmaceuticals Agrees To Acquire Amoun Pharmaceutical" (Press release). PRNewswire. July 17, 2015.
"Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals" (Press release). PRNewswire. August 20, 2015.
"Valeant Pharmaceuticals To Acquire Synergetics USA" (Press release). PRNewswire. September 2, 2015.
"Valeant To Sell CeraVe, AcneFree And AMBI Skincare Brands To L'Oreal For $1.3 Billion" (Press release). PRNewswire. January 10, 2017.
"Sanpower Group Agrees to Acquire Dendreon From Valeant for $819.9 Million" (Press release). PRNewswire. January 10, 2017.

propublica.org (Global: 3,281^st place; English: 1,880^th place)

Ornstein, Charles (October 27, 2015). "Federal Investigators Looking at Valeant's Contact Lens Dealings". ProPublica.

reuters.com (Global: 49^th place; English: 47^th place)

reuters.com

"UPDATE 1-Valeant Q1 profit beats Street; to acquire Aton Pharma". Reuters. May 3, 2010.
"Drugmaker Biovail to buy Valeant in $3.3 billion deal". Reuters. June 21, 2010. Archived from the original on October 6, 2015. Retrieved July 3, 2017.
Carl O'Donnell (October 29, 2015). "Valeant's ambitious plan for its contact lens business". Reuters.
Euan Rocha (February 4, 2014). "Valeant to buy PreCision Dermatology for $475 million". Reuters. Archived from the original on November 2, 2015. Retrieved July 3, 2017.
"Drugmaker Valeant completes $11 billion purchase of Salix". Reuters. 2015-04-01. Retrieved 2020-04-28.
Beasley, Deena (January 28, 2016). "Clinton targets Valeant price hikes in campaign appearance". Reuters. Retrieved July 17, 2016.
Pierson, Brendan (May 29, 2020). "CORRECTED: Special master says he will approve $1.21 bln Bausch securities settlement". Reuters – via www.reuters.com.
"Bausch Health agrees to pay $1.21 billion to settle share price lawsuit". Reuters. 2019-12-16. Retrieved 2019-12-16.

uk.reuters.com

Grover, Divya (10 August 2023). "Valeant looks to trim debt pile with $930 million iNova sale". Archived from the original on June 9, 2017.
"Valeant to sell Obagi Medical Products business for $190 million". 10 August 2023. Archived from the original on July 18, 2017.
"Valeant to sell female libido pill business back to former owners". reuters.com. Archived from the original on November 6, 2017. Retrieved 7 April 2018.

sec.gov (Global: 572^nd place; English: 436^th place)

"FORM 8-K".
"Pharmaceutical Company and Former Executives Charged With Misleading Financial Disclosures". Retrieved 14 June 2021.

senate.gov (Global: 758^th place; English: 500^th place)

aging.senate.gov

"Valeant Pharmaceuticals' Business Model: the Repercussions for Patients and the Health Care System", United States Senate Special Committee on Aging, April 27, 2016, retrieved April 29, 2016

thestreet.com (Global: 4,625^th place; English: 2,767^th place)

Elizabeth Gurdus (10 January 2017). "Valeant CEO: Drugmaker Knee-Deep in 'Turnaround Effort of a Lifetime'". The Street.

tipranks.com (Global: low place; English: low place)

"Salix Pharmaceuticals announces Phase 2 investigator-initiated study of RELISTOR". Tipranks. Archived from the original on 2024-03-31. Retrieved 2024-03-31.

valeant.com (Global: low place; English: low place)

ir.valeant.com

"Valeant Agrees To Sell Sprout Pharmaceuticals Subsidiary To Former Shareholders Of Sprout Pharmaceuticals". ir.valeant.com. Retrieved 7 April 2018.

valeantsecuritiessettlement.com (Global: low place; English: low place)

"NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION" (PDF). Valeant Securities Settlement. 2020-01-23. Retrieved 2023-12-16.

web.archive.org (Global: 1^st place; English: 1^st place)

"Panic Gone, New ICN Team Finds Finances in Disarray". Los Angeles Business Journal. 29 July 2002. Archived from the original on 11 January 2018. Retrieved 10 January 2018.
"ICN Pharmaceuticals, Inc. Changes Its Name To Valeant Pharmaceuticals International" (Press release). PRNewswire. November 12, 2003. Archived from the original on April 9, 2016. Retrieved March 28, 2016.
"Sweden's Meda AB Buys American Valeant Pharmaceuticals International Units for 392 Million" (Press release). Business Wire. August 4, 2008. Archived from the original on October 11, 2014. Retrieved October 7, 2014.
"Valeant to Acquire Tecnofarma, A Mexican Generic Company" (Press release). PRNewswire. July 29, 2009. Archived from the original on April 5, 2016. Retrieved March 23, 2016.
"Valeant to Acquire Laboratoire Dr. Renaud in Canada" (Press release). PRNewswire. December 7, 2009. Archived from the original on April 5, 2016. Retrieved March 23, 2016.
"Drugmaker Biovail to buy Valeant in $3.3 billion deal". Reuters. June 21, 2010. Archived from the original on October 6, 2015. Retrieved July 3, 2017.
Euan Rocha (February 4, 2014). "Valeant to buy PreCision Dermatology for $475 million". Reuters. Archived from the original on November 2, 2015. Retrieved July 3, 2017.
Lawrence, Stacy (20 October 2015), "Valeant to acquire in-office noninvasive ocular allergy Dx startup Doctor's Allergy", Fierce Medical Devices, archived from the original on 17 November 2015, retrieved 13 November 2015
Grover, Divya (10 August 2023). "Valeant looks to trim debt pile with $930 million iNova sale". Archived from the original on June 9, 2017.
"Valeant to sell Obagi Medical Products business for $190 million". 10 August 2023. Archived from the original on July 18, 2017.
"Valeant to sell female libido pill business back to former owners". reuters.com. Archived from the original on November 6, 2017. Retrieved 7 April 2018.
"Salix Pharmaceuticals announces Phase 2 investigator-initiated study of RELISTOR". Tipranks. Archived from the original on 2024-03-31. Retrieved 2024-03-31.

worldcat.org (Global: 5^th place; English: 5^th place)

search.worldcat.org

Pollack, Andrew; Tavernise, Sabrina (October 4, 2015). "Valeant's Drug Price Strategy Enriches It, but Infuriates Patients and Lawmakers". The New York Times. ISSN 0362-4331. Retrieved October 4, 2015.
Rockoff, Jonathan D.; Whalen, Jeanne. "Valeant and Pharmacy More Intertwined Than Thought". Wall Street Journal. ISSN 0099-9660. Retrieved October 10, 2015.(subscription required)
"Bausch Health Plans $1.21 B Settlement Over Stock Plunge". The New York Times. Associated Press. 2019-12-16. ISSN 0362-4331. Retrieved 2019-12-16.

wsj.com (Global: 79^th place; English: 65^th place)

Rockoff, Jonathan (20 August 2015). "Valeant to Buy Maker of Women's Libido Drug for $1 Billion". The Wall Street Journal. Retrieved 20 August 2015.
Rockoff, Jonathan D.; Whalen, Jeanne. "Valeant and Pharmacy More Intertwined Than Thought". Wall Street Journal. ISSN 0099-9660. Retrieved October 10, 2015.(subscription required)
Jonathan D. Rockoff (January 20, 2016). "Valeant Pharmaceutical Interim CEO to Testify Before Congress Next Week". WSJ.

yahoo.com (Global: 38^th place; English: 40^th place)

finance.yahoo.com

Andrew Steele (25 April 2016). "Valeant Pharma (VRX) Names Former Perrigo (PRGO) CEO to Fill Position". Yahoo Finance.
"Bausch + Lomb Receives CE Mark From The European Commission For The Stellaris Elite Vision Enhancement System". Yahoo Finance. 8 January 2017.

Bausch Health (English Wikipedia)

ai-cio.com (Global: low place; English: low place)

bauschhealth.com (Global: low place; English: low place)

ir.bauschhealth.com

bauschhealth.com

biospace.com (Global: low place; English: 7,595th place)

bloomberg.com (Global: 99th place; English: 77th place)

businesswire.com (Global: 615th place; English: 407th place)

cbc.ca (Global: 115th place; English: 82nd place)

citronresearch.com (Global: low place; English: low place)

cnbc.com (Global: 220th place; English: 155th place)

cnn.com (Global: 28th place; English: 26th place)

money.cnn.com

fiercebiotech.com (Global: low place; English: 8,828th place)

fiercemedicaldevices.com (Global: low place; English: low place)

fiercepharma.com (Global: low place; English: 8,921st place)

financialpost.com (Global: 3,491st place; English: 1,999th place)

business.financialpost.com

forbes.com (Global: 54th place; English: 48th place)

fortune.com (Global: 433rd place; English: 284th place)

ft.com (Global: 210th place; English: 157th place)

ftc.gov (Global: 3,796th place; English: 2,268th place)

genengnews.com (Global: low place; English: 6,625th place)

ghostarchive.org (Global: 32nd place; English: 21st place)

goodjobsfirst.org (Global: low place; English: low place)

violationtracker.goodjobsfirst.org

healio.com (Global: low place; English: low place)

huffingtonpost.ca (Global: 2,253rd place; English: 1,475th place)

institutionalinvestor.com (Global: 6,763rd place; English: 3,694th place)

labusinessjournal.com (Global: low place; English: 6,428th place)

nytimes.com (Global: 7th place; English: 7th place)

ocregister.com (Global: 1,086th place; English: 618th place)

pressreader.com (Global: 953rd place; English: 647th place)

prnewswire.com (Global: 406th place; English: 258th place)

propublica.org (Global: 3,281st place; English: 1,880th place)

reuters.com (Global: 49th place; English: 47th place)

reuters.com

uk.reuters.com

sec.gov (Global: 572nd place; English: 436th place)

senate.gov (Global: 758th place; English: 500th place)

aging.senate.gov

thestreet.com (Global: 4,625th place; English: 2,767th place)

tipranks.com (Global: low place; English: low place)

valeant.com (Global: low place; English: low place)

ir.valeant.com

valeantsecuritiessettlement.com (Global: low place; English: low place)

web.archive.org (Global: 1st place; English: 1st place)

worldcat.org (Global: 5th place; English: 5th place)

search.worldcat.org

wsj.com (Global: 79th place; English: 65th place)

yahoo.com (Global: 38th place; English: 40th place)

finance.yahoo.com

biospace.com (Global: low place; English: 7,595^th place)

bloomberg.com (Global: 99^th place; English: 77^th place)

businesswire.com (Global: 615^th place; English: 407^th place)

cbc.ca (Global: 115^th place; English: 82^nd place)

cnbc.com (Global: 220^th place; English: 155^th place)

cnn.com (Global: 28^th place; English: 26^th place)

fiercebiotech.com (Global: low place; English: 8,828^th place)

fiercepharma.com (Global: low place; English: 8,921^st place)

financialpost.com (Global: 3,491^st place; English: 1,999^th place)

forbes.com (Global: 54^th place; English: 48^th place)

fortune.com (Global: 433^rd place; English: 284^th place)

ft.com (Global: 210^th place; English: 157^th place)

ftc.gov (Global: 3,796^th place; English: 2,268^th place)

genengnews.com (Global: low place; English: 6,625^th place)

ghostarchive.org (Global: 32^nd place; English: 21^st place)

huffingtonpost.ca (Global: 2,253^rd place; English: 1,475^th place)

institutionalinvestor.com (Global: 6,763^rd place; English: 3,694^th place)

labusinessjournal.com (Global: low place; English: 6,428^th place)

nytimes.com (Global: 7^th place; English: 7^th place)

ocregister.com (Global: 1,086^th place; English: 618^th place)

pressreader.com (Global: 953^rd place; English: 647^th place)

prnewswire.com (Global: 406^th place; English: 258^th place)

propublica.org (Global: 3,281^st place; English: 1,880^th place)

reuters.com (Global: 49^th place; English: 47^th place)

sec.gov (Global: 572^nd place; English: 436^th place)

senate.gov (Global: 758^th place; English: 500^th place)

thestreet.com (Global: 4,625^th place; English: 2,767^th place)

web.archive.org (Global: 1^st place; English: 1^st place)

worldcat.org (Global: 5^th place; English: 5^th place)

wsj.com (Global: 79^th place; English: 65^th place)

yahoo.com (Global: 38^th place; English: 40^th place)